peppersite
Peptidesubcutaneousoral

KPV

KPV is a three-amino-acid peptide, lysine-proline-valine, cut from the tail end of alpha-MSH, a natural anti-inflammatory hormone. It is studied in anti-inflammatory and gut-barrier research, mostly in animal models and laboratory cell experiments.

Researched for
InflammationGut HealthTissue RepairRecovery

At a glance

Type
Peptide
Given by
subcutaneous, oral
Evidence
Not yet audited here; the reference library calls it emerging
Reported amount
200 mcg per Peptide Dosing Protocols. All 3 sources
Typical vial
10 mg in 2 mL

How much to draw

Full calculator →
Your draw
4units
0.04 mL on a U-100 insulin syringe
5 mg/mL50 doses per vial
Amount per dose

Opened on 200 mcg, the figure Peptide Dosing Protocols reports for KPV, and a 10 mg vial in 2 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for KPV or for anything else, and nothing below has been checked against the study it came from.

200-500 mcg SC daily, or 250-500 mcg orally twice daily for gut-directed support
Frequency
once daily (SC) or twice daily (oral)4-8 weeks · 4-8 week cycles
Route
subcutaneous or oral
Reported by
Commonly published practitioner dosing range - provider confirmation required.
200-500 mcg per injection (SC); or oral capsules as directed
Frequency
Once daily (SC); 1-2 times daily (oral)
Route
subcutaneous or oral
Reported by
Peptide Protocol Wiki
Standard: 200-500 mcg once or twice daily · Low: 200 mcg/day SubQ · High: 500 mcg twice daily
Frequency
once or twice dailyWeeks 1-8+ · 4-8 weeks on, 2-4 weeks off
Route
oral, subcutaneous
Reported by
Peptide Dosing Protocols
What it saysKPV is commonly dosed at 200-500 mcg once or twice daily for gut health.
Reconstitution, as reported
  • Commonly 5 mg vials (injectable) or oral capsules · Reconstitute with bacteriostatic water (injectable form)
  • Bacteriostatic water
  • 2 mL BAC water
Not yet audited

We have not published an audit on KPV. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

KPV turns down specific inflammatory signals rather than suppressing the immune system broadly, and it is small and stable enough to survive the gut and be absorbed, which is unusual for a peptide. Researchers link this to NF-kB inhibition, to transport through PepT1, a carrier that inflamed intestinal tissue makes more of, and to a mechanism that skips melanocortin-receptor signalling, which is why it does not cause tanning. Laboratory work also reports suppression of TNF-driven inflammatory signalling in airway cells and direct activity against S. aureus and C. albicans. All published efficacy data comes from animal models and cell experiments, and no completed human trial has confirmed its effects, dosing or long-term safety.

In technical termsPotential anti-inflammatory signaling via melanocortin pathways.

What we don't know

Whether it works in people: all published results come from animal models and laboratory cell experiments. No completed human clinical trial has confirmed its effects or its long-term safety.

Plain peptide versus gel: our audit notes that almost every KPV result it could point to used a hydrogel carrying the peptide. That is not the same thing as the plain powder sold as KPV.

Immune effects: in animal work KPV has not produced the infection risk seen with corticosteroids, but this has not been confirmed in human trials. Its interaction with prescribed immune-modulating drugs has not been studied.

Comparison with GHK-Cu: no study has tested the two in the same model with the same endpoints, and no test of the two together has been published.

Reported side effects

Reported by users: mild and short-lived irritation at the injection site, occasional mild headache, and occasional stomach upset at higher oral doses. These are community-level reports, not trial data.

Not ruled out: no formal human safety trial has been completed and long-term safety data does not exist. KPV turns down specific inflammatory pathways rather than suppressing immunity broadly, and animal work has not shown the infection susceptibility seen with corticosteroids, but that distinction has not been confirmed in people. As with any research-use peptide, contamination, underdosing and incorrect labelling are real risks.

Who should avoid it

People who are pregnant or breastfeeding: no safety data exists.

People with known hypersensitivity to peptide compounds: listed as a caution in the reference library, with no reason given.

People with active complex infectious disease and no clinician oversight: KPV's inflammatory and antimicrobial signalling overlap.

People with active autoimmune disease taking prescribed immune-modulating drugs: the interaction has not been studied.

People with inflammatory bowel disease or similar conditions on prescription treatment: sources state KPV should not replace prescribed medication and should be raised with the treating clinician.

What gets monitored

Monitor symptom-level changes, injection-site condition, oral GI tolerance, and any new symptoms that prompt review with a clinician. (reported by Peptide Dosing Protocols)

Regulatory status

FDA approval: KPV is not FDA-approved. The reference entry describes it as sold as a research-use peptide outside FDA-approved channels.

Compounding: on July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding KPV to the list of substances pharmacies may compound. The vote is advisory and does not bind the FDA. Adding a substance to the list needs formal FDA rulemaking, and news reports from July 23 and 24, 2026 said the FDA had made no final decision. FDA staff scientists had objected, citing a lack of safety and effectiveness data. None of this is FDA approval of KPV as a drug.

Checked: November 2026.

Common questions

What is KPV peptide?

KPV is a three-amino-acid peptide, lysine-proline-valine, cut from the tail end of alpha-MSH, the body's natural anti-inflammatory hormone. Unlike melanotan-type peptides it skips melanocortin-receptor signalling.

What are KPV peptide benefits in research?

Preclinical and laboratory research has reported anti-inflammatory effects, antimicrobial activity and effects on skin inflammation. The gut-inflammation findings, in particular the PepT1 transport discovery, are described as the strongest part of the literature, but all of it remains preclinical.

What is the KPV peptide dosage in research planning?

Reported amounts and schedules for KPV differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

How is KPV reconstituted?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

Can KPV be taken orally?

Yes, oral use is a common research route, especially for gut-focused work. KPV's proline and valine resist gut enzymes, and its small size lets it cross through the PepT1 transporter, which inflamed intestinal tissue produces more of.

What are KPV's main side effects?

Community reports are usually mild: short-lived irritation at the injection site, occasional mild headache and occasional stomach discomfort. No formal human safety trial has been completed.

Does KPV cause tanning or pigmentation changes?

No. KPV does not bind the melanocortin receptors that drive pigmentation, so it works through a different mechanism than the rest of alpha-MSH and is generally modelled as non-pigmenting.

Is KPV FDA approved in 2026?

No, KPV is not FDA-approved. It is sold as a research-use peptide outside FDA-approved channels, so source quality, certificate-of-analysis verification and storage handling vary widely between suppliers.

Sources

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
BPC-157

BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.

GHK-Cu

GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.

LL-37

LL-37 is the active 37-amino-acid piece of the only known human cathelicidin, a natural germ-fighting protein made by white blood cells, skin cells and other tissue linings. It is studied in antimicrobial and innate-immunity research.

GLOW

GLOW is a combination sold as one vial, pairing three peptides: GHK-Cu, BPC-157 and TB-500. It is studied for skin quality, tissue repair and recovery, though no trial has tested the three together in people.

Glutathione

Glutathione (GSH) is a small molecule built from three amino acids, cysteine, glycine and glutamate, made by nearly every cell and most of all by the liver. It has been studied in people for skin lightening, liver enzymes in fatty liver disease, and Parkinson's disease.

Thymosin Alpha-1

Thymosin Alpha-1 (TA1) is a lab-made copy of a 28-amino-acid peptide that the thymus gland makes naturally. It is studied mostly in people as an immune treatment, and is approved in more than 35 countries for chronic hepatitis B, chronic hepatitis C and as an add-on in cancer care.